GenScript, Bachem, and the Peptide Supply-Capability Divide

Headline capacity says nothing about fit

Before the dimensions, a reality check. Both companies publish impressive capacity. GenScript’s custom peptide service ranges from crude to ≥98% purity at milligram-to-kilogram scale, runs sequences up to roughly 200 residues, and lists a very wide modification catalog. Bachem’s non-GMP custom synthesis spans 5 mg to 100 g and is backed by GMP sites inspected by the FDA, EMA, and Swissmedic, positioning it for commercial API supply. As headline positioning, these are strong and not really in dispute.

Пептидийн синтез

The table below is how the two compare on the dimensions that actually influence whether a program succeeds — and it doubles as the evaluation template for any partner you are considering.

The columns are illustrative, not a final verdict. That is the point of the framework: a supplier’s place in the table only becomes meaningful once you map it to your sequence, your stage, and the documentation your program must carry.

Modification expertise: the depth behind the menu

Every credible supplier lists dozens of modifications. N-terminal acetylation, C-terminal amidation, cyclization, PEGylation, lipidation, phosphorylation, glycosylation, stapled frameworks, unusual amino acids — the catalogs now overlap heavily. As an evaluator, treat a modification menu as a hypothesis, not proof. The real question is whether the supplier has solved your exact chemistry before and can show you the impurity profile.

Bachem’s own custom peptide synthesis documentation is unusually honest about application-matched purity bands — recommending >95% for NMR, crystallography, and quantitative assays, and ≥80% for qualitative Western blotting. It also lists genuinely advanced handles: multiple cyclization strategies including hydrocarbon-stapled peptides and multi-disulfide frameworks, native chemical ligation, retro-inverso backbones, D-amino acids, N-methylated residues, and chelators such as DOTA and DTPA. That is the profile of a manufacturer that does not stop at the easy end of a sequence.

GenScript approaches the same challenge from breadth. Its catalog spans a very large modification library and specialized formats such as cyclic peptides and peptide–drug conjugates, which suits teams hunting across many analogues in discovery. The distinction matters because a long modification list and demonstrated difficult-sequence success are not the same asset. If your sequence is hydrophobic, aggregation-prone, long, or carries multiple site-specific modifications, ask for references of comparable chemistry rather than counting line items.

When you are evaluating, probe with three questions: has this shop synthesized sequences with comparable difficulty (length, hydrophobicity, disulfide topology, number of modifications); what is the real success rate and purification strategy for your pattern; and can they point to an orthogonal confirmation that the modification sits where you specified? A supplier that answers the third well is rare and worth keeping. Specialists built for complex frameworks, such as an integrated custom peptide synthesis platform combining solid-phase, liquid-phase, and fermentation routes, often ship more useful differentiators here than headline capacity.

Labeling that is proven, not just attached

Labeling deserves its own criterion because it is where generic synthesis capability quietly breaks down. Biotin, a fluorophore, a click handle, or a stable isotope is not a routine input you bolt onto any peptide; the tag must be positioned site-specifically, kept intact through synthesis and purification, and shown analytically to sit where you planned. Many labs have accepted a “labeled peptide” that is actually a mixture of positional isomers — and discovered it mid-assay.

What to compare on this dimension: whether terminal and side-chain positions are genuinely available (for example lysine or cysteine placement), whether the partner offers linkers and spacers of controlled length and polarity, whether tags can be made cleavable when an assay needs it, and whether label position and integrity are verified by orthogonal mass analysis rather than assumed. Loose reporting of “biotinylated” or “FITC-labeled” without method detail is a red flag.

Bachem lists biotin at terminal and side-chain positions, fluorescent and dye-labeled peptides, clickable handles, and stable isotope labeling — all evidence of real capability. GenScript’s catalog similarly spans fluorescent, biotin, and isotope options within its broad service menu. The difference surfaces in the analytical proof a partner attaches to a labeled batch.

For labeled probes, a capable peptide labeling service should be able to explain separation strategy — for example a biotinylation route that distinguishes the tagged from the untagged population, or a linker system that keeps biotin sterically accessible to streptavidin. If a supplier treats labeling as “request a tag and it is added,” it is not the partner for an assay whose readout depends on where the fluorophore sits.

Analytical depth beyond a purity number

A purity percentage on a certificate is the floor of quality data, not the ceiling. Research-grade release typically reports identity by MS and purity by HPLC — adequate for many screening experiments and insufficient for anything that must hold up under review. The difference between suppliers often shows in what else can be called on: orthogonal confirmation of sequence, chiral integrity, aggregation state, counterion, residual solvent and water, net peptide content, эндотоксин, and sterility.

Bachem’s standard QC uses HPLC and MALDI-MS, with advanced options including amino-acid analysis, ESI-MS/MS, counterion content, and endotoxin analysis — an analytical footprint that scales to regulated work. GenScript’s public materials emphasize its quality systems and cGMP pathway, though with less visible analytical layering. For a buyer, the practical test is not which company names more instruments; it is whether the supplier can deliver the specific orthogonal evidence your stage requires and defend it methodologically.

Aggregation is a good differentiator to test. Hydrophobic or long sequences form soluble oligomers that a single reversed-phase run can miss. A deeper partner will offer a technique such as size-exclusion chromatography with multi-angle light scattering (SEC-MALS) to characterize aggregation directly, or chiral separation when stereochemical impurities are the risk. Any analytical claim should be traceable to a method — a peptide testing program that pairs dual-column RP-HPLC with ESI-MS/MS mapping and sequence confirmation reflects the depth a development program ends up needing.

Documentation: research-grade vs. process-development reality

The most underweighted criterion in supplier selection is documentation, because teams evaluate partners early, at research purity, and then discover the true paperwork burden only when they reach IND-enabling work. The gap between a research CoA and a process-development data package is enormous, and it is worth understanding before you commit to a single partner.

Research-grade material is documented by a batch-specific certificate of analysis: identity, HPLC purity, often mass spectrometry, and sometimes a chromatogram. That supports a screening decision and little else. Process-development and GMP-oriented supply add full lot traceability, master batch records with in-process data, validated or qualified methods, release testing against defined specifications, deviation and change control, raw-material traceability, an impurity-control strategy, and stability support. The EMA’s guideline on the development and manufacture of synthetic peptides frames the synthetic-peptide regulatory expectations that push documentation well past a single certificate.

The fastest way to gauge a partner is to ask what a batch actually ships with. If the answer is a CoA, a purity figure, and a chromatogram, you are looking at research-grade documentation, whatever label the supplier applies. If the supplier can produce lot traceability, batch records, validated methods, and an impurity rationale, it is operating at process-development depth. Buyers evaluating regulated programs should request that document set up front — COA contents, raw analytical data, traceability, and quality-system practice — because it reveals more about a vendor than any capacity claim.

Scale fit: matching the route to your stage

The biggest supplier is rarely the best-fit supplier, because scale fit is about whether the route transfers cleanly as your program grows, not whether a facility can make a lot of peptide. Success in discovery at the milligram scale does not guarantee success at the kilogram scale on the same route — purity can drop, impurities can accumulate, and yield can collapse if the purification and synthesis were never designed to move.

GenScript’s relevance here is the runway it builds for research-to-early-clinical work: its custom peptide service spans milligram to kilogram, with a research-to-cGMP pathway that lets a discovery team stay with one supplier into IND-enabling studies without an early vendor switch. Bachem’s strength is the other end of the curve — deep GMP infrastructure positioned for commercial API volume, with the analytical and regulatory integration that large-scale regulated supply demands. The mismatch risk is real in both directions: a program that outgrows a research-oriented shop must re-qualify routes and documentation, and a discovery program over-scoped for a commercial manufacturer can lose flexibility and speed.

The rule of thumb is to ask whether the same synthesis and purification strategy used at your current scale can be carried to your next scale, and whether the supplier can produce a batch at a pilot or development scale to prove it. For teams moving a molecule forward, support for milligram-to-kilogram route transfer under a single quality roof removes a principal source of handoff risk.

From exploratory research to process development

Capacity tells you a supplier can make a lot of one thing. It tells you nothing about whether the same supplier can support you through the transition from exploratory research — where speed, flexibility, and modification breadth win — to process development, where route optimization, impurity control, manufacturability review, and technology transfer take priority. These two modes demand different muscles, and few shops are equally strong at both.

Discovery programs reward a partner who can move fast across many sequences, throw in unusual modifications, and return clean identity and purity data. Process-development programs reward a partner who can lock a route, understand the impurity landscape, control it, and hand a documented, reproducible process to a GMP or clinical manufacturer. Choosing a partner means deciding which side of that line you sit on today — and realistically, where you will be in twelve to eighteen months.

А peptide process-development engagement can clarify the difference in practice: it typically spans route design — a chemical route for shorter sequences versus a recombinant route for long or complex ones — along with production optimization, purification strategy, and explicit impurity control to remove deletion sequences, mismatches, and oxidation products. That is a very different deliverable set from a research-grade synthesis, and it is worth checking whether a prospective partner can articulate both modes rather than claiming to do everything.

Putting the framework to work

If you are comparing peptide partners now, run each candidate through the six dimensions against your real program rather than a generic wishlist:

1. Write down your molecule and stage first. A long, hydrophobic, multi-disulfide peptide aimed at IND-enabling work is a different selection problem from a short screening peptide.

2. Score modification depth on your exact chemistry, not on catalog line items.

3. Ask how labeling position is proven, if a label matters to your assay.

4. List the analytical evidence your stage needs — orthogonality, aggregation, агуулга, counterion, endotoxin — and confirm the partner can run it.

5. Request the documentation package you will actually file, not the one that satisfies a screen.

6. Check the scale route transfers and confirm with a pilot or development batch.

7. Assess both research and process-development modes, and pick the one that matches your horizon.

The dividing line between GenScript and Bachem — like the line between any two capable partners — is not kilograms per year. It is how deeply each can serve your specific sequence at the right stage, with labeling you can trust, analytics you can defend, documentation you can file, and a scale route that survives the journey to the clinic.

When a vendor hands you a purity number and a capacity claim, ask for the orthogonal evidence, the batch records, and the demonstration that the route scales. The partner that can answer on all six dimensions is the one worth keeping — not the one with the largest headline. If you are comparing options now, a short technical conversation with a peptide specialist such as MOL Changes can map your sequence and stage against this framework and confirm which partner genuinely fits — see their integrated custom peptide services.